Background
Infection due to severe acute respiratory coronavirus 2 (SARS-CoV-2) may lead to an atypical acute respiratory distress syndrome (ARDS) [
1], requiring in the most severe cases veno-venous extracorporeal membrane oxygenation (VV-ECMO). The management of persistent severe hypoxemia under VV-ECMO requires a multi-step clinical approach including prone positioning (PP), which could improve oxygenation [
2].
Methods
We performed a retrospective study of patients with SARS-CoV-2-induced ARDS submitted to PP during VV-ECMO. We aimed to describe mechanical ventilation parameters and gas exchanges before and after PP. We assess the safety of PP and compare patients with PP under ECMO (prone ECMO group) to those maintained in the supine position (supine ECMO group). Patients were treated in accordance with the recommendation guidelines on ARDS [
3]. During VV-ECMO, PP was considered in case of severe hypoxemia (PaO
2/FiO
2 ratio below 80 mmHg) despite FDO
2 and FiO
2 both at 100% and in case of extensive lung consolidation (ECL) on chest imaging (> 50% of lung volume).
Results
We enrolled 208 COVID-19 patients. Among the 125 patients with ARDS, 25 (20%) required VV-ECMO, and 14 (56%) were placed at least once in PP for a total of 24 procedures with a median duration of 16 (15–17) h. The delay from ECMO implantation therapy to PP was 1.5 days [
1‐
3]. The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PP are displayed in Table
1. The median PaO
2/FiO
2 ratio improvement after PP was 28% [2–36]. High responders (increase PaO
2/FiO
2 ratio > 20%) were 62.5%, moderate-responders (increase PaO
2/FiO
2 < 20%) were 16.7%, and non-responders (decrease PaO
2/FiO
2) were 20.8%. We did not observe any major safety concerns but only pressure sores after 6 procedures, three minor hemorrhages at the injection cannula, and three moderate drops in VV-ECMO flow requiring fluid resuscitation. Pre-ECMO characteristics, ventilator/ECMO settings, and outcomes are exposed in Table
2. Patients in the prone ECMO group were less likely to be weaned from ECMO, and 28-day mortality rate was significantly higher.
Table 1
The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PP
Mechanical ventilation settings |
Tidal volume (mL/kg) | 2.4 (1.8–2.9) | 2.4 (1.8–2.7) | 0.42 |
RR (breaths/min) | 20 (16–25) | 19 (16–25) | 0.87 |
Plateau airway pressure (cmH2O) | 28 (26–32) | 29 (28–32) | 0.43 |
PEEP (cmH2O) | 14 (12–18) | 16 (12–20) | 0.36 |
Respiratory system compliance (mL/cmH2O) | 18.6 (13.7–25.9) | 17.9 (12.8–26.5) | 0.92 |
Driving pressure (cmH2O) | 14.5 (12–16.5) | 14.5 (11–16) | 0.56 |
Inspired fraction of oxygen (%) | 70 (60–100) | 67.5 (52.5–95) | 0.16 |
ECMO settings |
ECMO blood flow (L/min) | 6.2 (6–6.7) | 6 (5.8–6.7) | 0.41 |
Sweep gas flow (L/min) | 7 (6–8.5) | 7 (6.8–9) | 0.15 |
FDO2 (%) | 100 (80–100) | 100 (80–100) | 0.56 |
Gas analysis |
PaO2 (mmHg) | 64 (51–78) | 82 (66–109) | 0.007 |
PaO2/FiO2 (mmHg) | 84 (73–108) | 112 (83–157) | 0.002 |
PaCO2 (mmHg) | 44 (41–46) | 42 (36–49) | 0.27 |
pH | 7.38 (7.35–7.43) | 7.38 (7.34–7.42) | 0.47 |
Table 2
Pre-ECMO characteristics, ventilator/ECMO settings, and outcomes
Age (years) | 59 (49.5–63) | 59 (48–63) | 57 (48–66) | 0.82 |
Male sex, n (%) | 22 (88) | 12 (85.7) | 10 (90.9) | 1 |
Body mass index (kg/m2) | 32 (28.4–37.5) | 31.5 (28–38) | 33.6 (28.4–37.6) | 0.86 |
Comorbidities |
Any, n (%) | 6 (24) | 3 (21.4) | 3 (27.3) | 1 |
Hypertension, n (%) | 12 (48) | 6 (42.8) | 6 (54.5) | 0.7 |
Diabetes, n (%) | 10 (40) | 5 (35.7) | 5 (45.4) | 0.7 |
SAPS II | 60 (40–65) | 59.5 (46–62) | 61 (38–80) | 0.39 |
Delay symptoms-ECMO (days) | 16 (11–18) | 15 (11–20) | 16 (10–16) | 0.94 |
Delay mechanical ventilation-ECMO (days) | 7 (4–10) | 6.5 (4–10) | 7 (4–13) | 0.99 |
Chest imaging (X-rays or CT) |
Consolidation, n (%) | 14 (56%) | 11 (78.6) | 3 (27.3) | 0.02 |
Ground glass opacity, n (%) | 25 (100) | 14 (100) | 11 (100) | – |
Bilateral infiltration, n (%) | 25 (100) | 14 (100) | 11 (100) | – |
PaO2/FiO2 ratio before ECMO (mmHg) | 84 (69–98) | 84 (67–96) | 87 (66–102) | 0.77 |
Prone position before ECMO, n (%) | 25 (100) | 14 (100) | 11 (100) | – |
Neuromuscular blockers, n (%) | 25 (100) | 14 (100) | 11 (100) | – |
iNO before ECMO, n (%) | 21 (84) | 12 (85.7) | 9 (81.8) | 1 |
Corticosteroids, n (%) | 4 (16) | 1 (7.1) | 3 (27.3) | 0.29 |
MV and ECMO settings the first day of ECMO |
Tidal volume (mL/kg) | 2.6 (1.9–2.9) | 2.4 (1.7–3.1) | 2.6 (2.1–2.8) | 0.71 |
Plateau airway pressure (cmH2O) | 26 (23–29) | 26 (25–29) | 26 (21–29) | 0.52 |
PEEP (cmH2O) | 14 (11–20) | 14 (12–20) | 14 (10–20) | 0.47 |
Driving pressure (cmH2O) | 10 (9–13) | 11 (10–14) | 9 (8–12) | 0.44 |
Respiratory rate (cycles/min) | 14 (12–18) | 18 (13–25) | 12 (12–14) | 0.006 |
Respiratory system compliance (mL/cmH2O) | 25 (15–32) | 24 (14–30) | 28 (18–33) | 0.36 |
Inspired fraction of oxygen (%) | 50 (50–80) | 55 (50–72.5) | 50 (40–80) | 0.53 |
ECMO blood flow (L/min) | 5.9 (5–6.3) | 5.8 (5.2–6.7) | 5.9 (4.9–6) | 0.31 |
Sweep gas flow (L/min) | 5 (4–6) | 5.5 (4.5–6.2) | 4 (3.5–5) | 0.04 |
Membrane lung fraction of oxygen (%) | 100 (80–100) | 100 (80–100) | 100 (90–100) | 0.38 |
Outcomes |
ECMO weaning, n (%) | 11 (44) | 3 (21.4) | 8 (72.7) | 0.02 |
ECMO duration (days) | 10 (5–13) | 11 (6–13) | 6 (3–12) | 0.28 |
28-day mortality, n (%) | 14 (56) | 11 (78.6) | 3 (27.3) | 0.02 |
Discharged alive from ICU, n (%) | 10 (40) | 2 (14.3) | 8 (72.7) | 0.005 |
Still in ICU, n (%) | 1 (4) | 1 (7.1) | 0 | 1 |
Discussion
We report that during VV-ECMO, PP improved oxygenation without a change in respiratory system compliance and PaCO
2 at constant levels of minute ventilation and sweep gas flow. This does not suggest lung recruitment by PP but rather an optimization of ventilation and perfusion matching. Three explanations could be advanced for the mortality rate in the prone ECMO group (78.6%). First, prone ECMO patients may be more severe than supine ECMO patients. As described by Gattinoni et al., worsening patients progress from type 1 to type 2 (higher percentage of non-aerated tissue) [
1], which is associated with a higher mortality rate [
4]. Prone ECMO patients had much more consolidations, obviously because ECL was the main indication to be prone (
n = 10/14). Furthermore, prone ECMO patients need a higher respiratory rate for a higher sweep gas flow suggesting that they may be exposed to a higher mechanical power, and they possibly had also a higher dead space. Second, postmortem biopsies, performed in 6 patients with ECL in the prone ECMO group, found a fibrin exudative presence both in the alveolar spaces and bronchioles followed by a fibroblastic phase [
5] and raise the question of the use of corticosteroids (only one patient in the prone ECMO group). Third, as already described by Zeng et al. [
6], more than half (8/11) of the patients died from septic shock and multiple organ failure, for which ECMO may be useless.
Conclusion
Prone positioning under VV-ECMO improves oxygenation in SARS-CoV-2-induced ARDS without compromising the safety of the patients. The high mortality rate in prone ECMO patients may be explained by the greater illness severity and the lack of an immunomodulatory therapy such as corticosteroids.
Acknowledgements
The authors are indebted to thank the whole members of the Lille Intensive Care COVID-19 Group and the entire nursing staff of the intensive care unit of the “Roger Salengro Hospital” of the “Centre Hospitalier Universitaire de Lille.”.
Lille Intensive Care COVID-19 group:
Pauline Boddaert1 (Pauline.boddaert@chru-lille.fr), Arthur Durand1 (Arthur.durand@chru-lille.fr), Ahmed El Kalioubie1 (Ahmed.elkalioubie@chru-lille.fr), Patrick Girardie1 (Patrick.girardie@chru-lille.fr), Marion Houard1 (Marion.houard@chru-lille.fr), Geoffrey Ledoux1 (Geoffrey.ledoux@chru-lille.fr), Anne Sophie Moreau1 (Annesophie.moreau@chru-lille.fr), Christopher Niles1 (Christopher.niles@chru-lille.fr), Saad Nseir1 (Saad.nseir@chru-lille.fr), Thierry Onimus1 (Thierry.onimus@chru-lille.fr), Aurelia Toussaint1 (Aurelia.toussaint@chru-lille.fr), Sebastien Préau1 (Sebastien.preau@chru-lille.fr), Laurent Robriquet1 (Laurent.robriquet@chru-lille.fr), Anahita Rouze1 (Anahita.rouze@chru-lille.fr), Arthur Simonnet1 (Arthur.simonnet@chru-lille.fr), Sophie Six1 (Sophie.six@chru-lille.fr), Morgan Caplan1 (morgan.caplan@chru-lille.fr), Julien Goutay1 (julien.goutay@chru-lille.fr), Emmanuelle Jaillette1 (emmanuelle.jaillette@chru-lille.fr), Erika Parmentier-Decrucq1 (erika.decrucq@chru-lille.fr), Raphael Favory1 (raphael.favory@chru-lille.fr), Daniel Mathieu1 (daniel.mathieu@chru-lille.fr), Guillaume Degouy (Guillaume.degouy@chru-lille.fr), Mouhamed Moussa2 (Mouhamed.MOUSSA@CHRU-LILLE.FR)
1Pôle de Réanimation, CHU Lille, University of Lille, F-59000 Lille, France
2Service d’Anesthésie-Réanimation Cardio-Vasculaire, CHU Lille, University of Lille, F-59000 Lille, France
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.